Elexacaftor + Tezacaftor + Ivacaftor
This combination is a prescription medication used to treat cystic fibrosis in patients with specific genetic mutations. It contains three active ingredients: elexacaftor, tezacaftor, and ivacaftor. These drugs work together to improve lung function and decrease the frequency of exacerbations in patients with cystic fibrosis.Cystic fibrosis in patients aged 12 years and older who have at least one F508del mutation in the CFTR gene.
-The usual recommended dosage for patients 12 years and older is one tablet containing elexacaftor (100 mg), tezacaftor (50 mg), and ivacaftor (150 mg) once daily in the morning. Additionally, a second tablet containing ivacaftor (150 mg) should be taken in the evening. -Follow the prescribing healthcare professional's instructions on dosage and administration.
Known hypersensitivity to any of the active or inactive ingredients in the medication.
-Monitor liver function periodically as the drug can cause elevations in liver enzymes. -Use caution in patients with moderate to severe liver impairment. -Advise patients to avoid grapefruit or Seville oranges, as they can interact with the drug. -Caution should be taken in patients with cataracts or a history of cataracts.
-Common side effects include headache, dizziness, upper respiratory tract infection, abdominal pain, and diarrhea. -Serious side effects can include elevated liver enzymes, rash, and cataracts.
-Avoid use with strong CYP3A inhibitors and inducers, as they can affect the plasma levels of the active ingredients. -Concomitant use with CYP3A substrates may require dose adjustments.
